130 related articles for article (PubMed ID: 25695224)
1. Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases.
Gleeson FC; Kipp BR; Levy MJ; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Lazaridis KN; Kerr SE
J Thorac Oncol; 2015 Mar; 10(3):531-4. PubMed ID: 25695224
[TBL] [Abstract][Full Text] [Related]
2. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
3. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
4.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
5. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
6. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
Schabath MB; Welsh EA; Fulp WJ; Chen L; Teer JK; Thompson ZJ; Engel BE; Xie M; Berglund AE; Creelan BC; Antonia SJ; Gray JE; Eschrich SA; Chen DT; Cress WD; Haura EB; Beg AA
Oncogene; 2016 Jun; 35(24):3209-16. PubMed ID: 26477306
[TBL] [Abstract][Full Text] [Related]
7. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
9. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ
Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.
Marks JL; Broderick S; Zhou Q; Chitale D; Li AR; Zakowski MF; Kris MG; Rusch VW; Azzoli CG; Seshan VE; Ladanyi M; Pao W
J Thorac Oncol; 2008 Feb; 3(2):111-6. PubMed ID: 18303429
[TBL] [Abstract][Full Text] [Related]
11. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
[TBL] [Abstract][Full Text] [Related]
12. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV
Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186
[TBL] [Abstract][Full Text] [Related]
13. A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
Chen L; Engel BE; Welsh EA; Yoder SJ; Brantley SG; Chen DT; Beg AA; Cao C; Kaye FJ; Haura EB; Schabath MB; Cress WD
J Thorac Oncol; 2016 Jun; 11(6):838-49. PubMed ID: 26917230
[TBL] [Abstract][Full Text] [Related]
14. Molecular Signatures of
Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
Baum JE; Zhang P; Hoda RS; Geraghty B; Rennert H; Narula N; Fernandes HD
Cancer Cytopathol; 2017 Jun; 125(6):398-406. PubMed ID: 28272845
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
[TBL] [Abstract][Full Text] [Related]
17. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
18. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sanchez-Cespedes M; Parrella P; Esteller M; Nomoto S; Trink B; Engles JM; Westra WH; Herman JG; Sidransky D
Cancer Res; 2002 Jul; 62(13):3659-62. PubMed ID: 12097271
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing.
Gleeson FC; Kipp BR; Levy MJ; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Lazaridis KN; Kerr SE
Cancer Cytopathol; 2014 Nov; 122(11):822-32. PubMed ID: 25045116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]